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Globally, non-communicable diseases now account for most deaths, with 
cardiovascular disease and cancer at the top of this unfortunate league table. In 
2017, in Western Europe, 29% of deaths were attributed to cancer and 33% to 
cardiovascular diseases1; in the USA, 21% were attributed to cancer and 23% to 
heart disease2. Unfortunately, many people get both cardiovascular disease and 
cancer. Most people who die from cardiovascular disease will first develop heart 
failure even if it is not recorded as the cause of death3 and amongst incident cases of 
heart failure, 25% will already have a history of cancer4 and 15% may subsequently 
die of cancer5.  
 
Heart failure and cancer share many common risk factors (e.g. obesity and 
smoking), many common symptoms (dyspnoea, fatigue, oedema, weight loss) and 
many similar complications, including depression, anaemia, iron deficiency and 
cachexia6. Cancer and its treatment may cause heart failure or aggravate pre-
existing cardiac dysfunction. There may also be biological mechanisms by which 
heart failure enhances tumour growth7, whilst clonal haematopoiesis of indeterminate 
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potential (CHIP) provides a common stem for the development of heart failure and 
cancer7. 
 
The two largest studies investigating a potential epidemiological link between 
heart failure and the subsequent development of cancer, have shown contradictory 
results. An analysis of hospital administrative records in Denmark8 identified 9,307 
patients with heart failure who were not known to have cancer at the time of 
diagnosis. Of these, 975 developed cancer during a mean follow-up of 4.5 years (SD 
±2.3 years). Compared to patients without heart failure, the incidence rate ratio for 
developing any type of cancer was 1.24 (95% CI 1.15–1.33) after adjusting for age 
and sex, but not for other common risk factors for heart failure and cancer. In 
contrast, an analysis of data from 28,341 participants in the Physicians' Health 
Studies programme9, comprising two randomized controlled trials testing aspirin and 
vitamin supplements, identified 1,420 new cases of heart failure and 7,363 new 
cases of cancer during a median follow-up of 20 years but found no association 
(crude HR 0.92; 95%CI 0.80–1.08). 
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 In this issue, Bayés-Genís et al10 report mortality and cause of death amongst 
1,876 patients with heart failure and a left ventricular ejection fraction <50% at a 
single clinic in a tertiary cardiac centre in Spain. Median follow-up, censored for 
death (a statistical convention that clinicians should not necessarily adopt), was 4.2 
years. During this time, 935 patients died. Although most deaths were 
cardiovascular, 138 (15%) people died of cancer, a similar proportion to that reported 
in the UK from a similar clinic11 and a large administrative data-base5. This is a much 
lower proportion than die with cancer in the general population, which is not 
surprising given the high mortality related to cardiorespiratory disease in patients with 
heart failure. The authors go on to suggest that the proportion of deaths due to non-
cardiovascular causes has risen over the last 20 years from less than 20% to more 
than 60% and that the proportion due to cancer has risen from less than 5% to more 
than 20%. However, in the period with the most robust data (2010-17) there was little 
evidence of a change in the mode of death. Adjudications in earlier periods might 
have been less robust before the clinical service, data-acquisition and adjudication 
procedures were fully mature. Conrad et al5, using administrative data from primary 
and secondary care in the UK, identified 86,833 incident cases of heart failure 
Page 5 of 11 
 
between 2002 and 2013. In this period, the proportion of deaths within one year of 
diagnosis that were cardiovascular fell from 52% to 43%, the proportion of deaths 
due to cancer was stable (14% to 15%) but deaths due to infection and/or respiratory 
disease rose from 18% to 25%. For those aged 80 years or less, all-cause mortality 
at one year fell by 21% due to a marked decline in cardiovascular mortality with little 
change in non-cardiovascular deaths. In contrast, all-cause mortality at one year was 
unchanged in older people, despite a 26% reduction in cardiovascular mortality, 
because it was offset by a rise in non-cardiovascular deaths, suggesting that current 
treatments for heart failure might modify how older patients die but do not prolong 
their lives. 
 
Clinical trials of patients with heart failure and a reduced left ventricular 
ejection fraction (HFrEF) suggest that about 80% of deaths are cardiovascular, 
although perhaps only 25% die ‘of’ heart failure. Fewer than 10% of deaths are 
attributed to cancer, with little evidence of a change in the last 20 years (Figure 1). 
However, by design, clinical trials select patient-characteristics in order to enrich the 
population for the sorts of events that the intervention is designed to influence. 
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Clinical trials of heart failure with a preserved left ventricular ejection fraction 
(HFpEF) report a higher proportion of non-cardiovascular deaths (Figure 1), which 
may be one reason why so many have failed to show that treatments targeting 
cardiovascular disease improve outcome. Data from a clinic in the UK11, similar to 
that described by Bayés-Genís et al10, suggests a similarly higher proportion of 
deaths for non-cardiovascular reasons amongst people with HFrEF or HFpEF than 
observed in clinical trials (Figure 1). From a clinical trialists perspective, it is important 
to select patients who might benefit from the intervention being studied, whether it is 
for cancer or for heart disease. Older patients are more likely to have or develop 
multiple diseases that may confound the interpretation of trials aimed at a specific 
therapeutic target. Although treatments that are effective in younger patients with few 
comorbidities cannot be assumed to improve outcome in older people, younger 
patients should not be denied effective treatments just because trials conducted in 
older multi-morbid patients failed to show benefit. 
 
Classification of clinical events, including death, is an evolving art that does 
not have a sound scientific basis. Classification depends heavily on the interpretation 
Page 7 of 11 
 
of small words such as “of”, “from” and “with”. Oncologists are often uncertain about 
the cause of death in their patients; many will die “with” cancer but not “of” cancer. 
Indeed, analysis of 816 autopsies on patients who died whilst being treated for 
cancer found a cardiovascular cause for death in 194 (24%) cases (Figure 2)12. 
Deaths due to myocardial infarction, stroke or pulmonary embolism might appear 
unrelated to cancer13 but inflammation may cause vascular damage and activate 
coagulation pathways leading to fatal thrombotic events. Other causes of death in 
patients with cancer include infection, renal failure and suicide. Many patients who 
have incurable cancer will not actually die of cancer. All of these considerations also 
hold true for heart failure. Most patients with heart failure don’t die of heart failure; 
they die suddenly, or they get respiratory or urinary infections with septicaemia and 
multi-organ failure, or they have myocardial infarctions and strokes, or they get old 
and develop dementia; some will die “of” heart failure but many more will die “with” 
heart failure. As treatments for heart failure extend life, it is inevitable that more 
patients with heart failure will get cancer. Similarly, discovery of more effective 
treatments for cancer will lead to more people developing heart failure. Ultimately, 
most people now die due to a conspiracy of diseases and not a single lethal problem. 
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Newer approaches to adjudication reflect this and no longer just report the primary 
cause of events but include other factors that conspire to produce an adverse 
outcome.  
 
Treating heart failure and cancer, two malignant diseases, at the same time is 
challenging for both oncologists and cardiologists.14,15,16 Many centres of excellence 
have established cardio-oncology services to evaluate the risk of cardiotoxicity, 
monitor the effects of therapy on cardiac function, ensure that curative treatment for 
cancer is not inappropriately withheld and manage patients who develop cardiac 
dysfunction and heart failure whilst being treated for cancer17,18. We must hope that 
all patients with heart failure have access to similar resources for their care when 
needed and not just those with two malignant diseases rather than just one. 
 
In conclusion, an increase in the number of people developing cancer is an 
unfortunate consequence of the success in delaying the onset of heart failure into 
older age and greater longevity after heart failure has developed. Successful 
prevention and treatment of cancer is likely to have the same effect on the number of 
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people developing heart failure. Those unfortunate enough to develop multiple, 
debilitating, incurable conditions may become reluctantly reconciled to dying but 
perhaps, for some, death may be postponed too long7?  
Page 10 of 11 
 
References 
1 Ritchie H, Roser M. Causes of Death. https://ourworldindata.org/causes-of-death 
 
2 Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. 
NCHS Data Brief. 2018;328:1-8. 
 
3 Torabi A, Rigby AS, Cleland JG. Declining in-hospital mortality and increasing heart 
failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 
2009;55:79-81 
 
4 Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, 
Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns 
in heart failure incidence: a population-based study of 4 million individuals. Lancet. 
2018;391:572-580. 
 
5 Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes AC, Millett ERC, Salimi-
Khorshidi G, Cleland JG, McMurray JJV, Rahimi K. Temporal Trends and Patterns in 
Mortality After Incident Heart Failure: A Longitudinal Analysis of 86 000 Individuals. 
JAMA Cardiol. 2019 Sep 3. [Epub ahead of print] 
 
6 Lena A, Coats AJS, Anker MS. Metabolic disorders in heart failure and cancer. 
ESC Heart Fail. 2018;5:1092-1098. 
 
7 Cleland JGF, van Veldhuisen DJ, Ponikowski P. The year in cardiology 2018: heart 
failure. Eur Heart J. 2019;40:651-661. 
 
8 Banke A, Schou M, Videbaek L, Møller JE, Torp-Pedersen C, Gustafsson F, Dahl 
JS, Køber L, Hildebrandt PR, Gislason GH. Incidence of cancer in 
patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail 
2016;18:260–266.  
 
9 Selvaraj S, Bhatt DL, Claggett B, Djoussé L, Shah SJ, Chen J, Imran TF, Qazi S, 
Sesso HD, Gaziano JM, Schrag D. Lack of association between heart failure and 
incident cancer. J Am Coll Cardiol 2018;71:1501–1510. 
   
10 Bayés-Genís A, Moliner P, Josep Lupón J, Marta De Antonio M de, Mar Domingo 
M, Evelyn Santiago-Vacas E, Elisabet Zamora E, German Cediel G, Javier 
Santesmases J, Crisanto Diez-Quevedo C, Maria Isabel Troya MI, Maria Boldo M, 
Salvador Altimir S, Nuria Alonso N, Beatriz Gonzalez B, Nuñez J. Trends in Modes of 
Death in Heart Failure over the Last Two Decades: Less Sudden Death but Cancer 
Deaths on the Rise.  
 
11 Cleland JG, Zhang J, Pellicori P, Dicken B, Dierckx R, Shoaib A, Wong K, Rigby 
A, Goode K, Clark AL. Prevalence and Outcomes of Anemia and Hematinic 
Deficiencies in Patients With Chronic Heart Failure. JAMA Cardiol. 2016;1:539-47.  
                                                 
Page 11 of 11 
 
                                                                                                                                                        
 
12 Inagaki J, Rodriguez V, Bodey GP. Proceedings: cause of death in cancer 
patients. Cancer. 1974;33:568-73. 
 
13 Kendal WS. Dying with cancer: the influence of age, comorbidity, and cancer site. 
Cancer. 2008;112:1354-62. 
 
14 Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler-Klein J, Cohen-Solal A, 
Farmakis D, López-Fernández T, Lainscak M, Pudil R, Ruschitzka F, Seferovic P, 
Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, 
Tocchetti CG; Heart Failure Association Cardio-Oncology Study Group of the 
European Society of Cardiology. Cancer diagnosis in patients with heart failure: 
epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail. 
2018;20:879-887.  
 
15 Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, 
Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, 
Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach 
S, Agewall S, Badimon L, Barón-Esquivias G, Baumgartner H, Bax JJ, Bueno H, 
Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti 
P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz 
Carneiro A, Windecker S; Authors/Task Force Members; ESC Committee for 
Practice Guidelines (CPG); Document Reviewers. 2016 ESC Position Paper on 
cancer treatments and cardiovascular toxicity developed under the auspices of the 
ESC Committee for Practice Guidelines: The Task Force for cancer treatments and 
cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 
2017;19:9-42.  
 
16 Anker MS, Lena A, Hadzibegovic S, Belenkov Y, Bergler-Klein J, de Boer RA, 
Cohen-Solal A, Farmakis D, von Haehling S, López-Fernández T, Pudil R, Suter T, 
Tocchetti CG, Lyon AR; Heart Failure Association Cardio-Oncology Study Group of 
the European Society of Cardiology. Modern-day cardio-oncology: a report from the 
'Heart Failure and World Congress on Acute Heart Failure 2018'. ESC Heart Fail. 
2018;5:1083-1091.  
 
17 Farmakis D, Keramida K, Filippatos G. How to build a cardio-oncology service? 
Eur J Heart Fail. 2018;20:1732-1734.  
 
18 Pareek N, Cevallos J, Moliner P, Shah M, Tan LL, Chambers V, Baksi AJ, Khattar 
RS, Sharma R, Rosen SD, Lyon AR. Activity and outcomes of a cardio-oncology 
service in the United Kingdom-a five-year experience. Eur J Heart Fail. 
2018;20:1721-1731. 
 
